ClinicalTrials.gg
CompletedNCT00159913Updated Feb 18, 2021Results posted

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

A Phase 3 interventional study of Sildenafil citrate and Sildenafil citrate in Pulmonary Arterial Hypertension, Children, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 41 sites in 17 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
2nd of 18
235 · median 23
Started
2003
with 1 other
Phase 3
7 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
7 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 2nd largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 3, and was the 1st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years. The purpose of the study is to assess the efficacy, safety, and pharmacokinetics of 16 weeks of chronic treatment with oral sildenafil given in three different doses, compared to placebo (inactive treatment). Efficacy will be measured by exercise and hemodynamics. Patients who complete this trial may be eligible to take part in an extension study, in which all patients will receive active treatment of sildenafil.

03

Conditions studied

  • Pulmonary Arterial Hypertension, Children
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged from 1 to 17 years old and weighing >= 8 kg with a mean pulmonary artery pressure >= 25 mmHg at rest, PCWP \<= 15 mmHg, and PVRI >= 3 Wood units x m2 (if PCWP is not available, then mean LA pressure \<= 15 mmHg or LVEDP \<= 15 mmHg in the absence of left atrial obstruction).
  • Females of child bearing potential who were sexually active must have been practicing a suitable method of so that in the opinion of the investigator, they would not become pregnant during the study.
  • Subjects who have symptomatic pulmonary arterial hypertension due to: primary pulmonary hypertension; pulmonary arterial hypertension in the presence of a small or hemodynamically insignificant congenital systemic to pulmonary shunt lesion that in the opinion of the investigator is not the cause of pulmonary hypertension; collagen vascular disease; congenital systemic-to-pulmonary shunts with a baseline resting room air oxygen saturation >= 88% unrepaired or repaired at least 6 months prior to screening; d-transposition of the great arteries repaired within the first 30 days of life; or surgical repair of other congenital heart lesions at least 6 months prior to screening and do not have residual left-sided heart disease consistent with the exclusion criteria.
  • Subjects, developmentally able to exercise, whose CPX exercise test functional capacity is within the following parameters: Peak VO2 >= 10 mL/kg/min and \<= 28 mL/kg/min during screening CPX test;
  • Written and assent where applicable before the subject is screened for the study.
  • Subjects who undergo a large shift in altitude (defined as approximately 5000 feet or 1524 meters) in order to participate in the study must reside at the "in study" altitude for at least 90 days prior to baseline and during the study period.

Exclusion criteria

Exclusion Criteria:

  • Subjects with pulmonary hypertension secondary to sickle cell disease, any other disease known to be associated with PAH, or any etiology other than those specified in the inclusion criteria.
  • Left-sided heart disease, including aortic or mitral valve disease (greater than mild), restrictive or congestive cardiomyopathy; PCWP or LVEDP > 15 mmHg; \< 40% determined by MUGA, angiography or echocardiography; LV shortening fraction \< 22% determined by echocardiography, symptomatic coronary disease (demonstrable ischemia).
  • Pericardial constriction; significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation; acutely decompensated heart failure within previous 30 days from screening; atrial septostomy within previous 6 months of screening;
  • Hemodynamic instability or hypo- or hypertension at screening, i.e., SBP outside of 70-140 mmHg.
  • A history of stroke, myocardial infarction or life threatening arrhythmia within 6 months of screening.
  • Moderate to severe restrictive pulmonary disease (Total Lung Capacity or Forced Vital Capacity \<= 60% of normal) or history of severe lung disease.
  • Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.
  • History of pulmonary embolism.
  • Subjects whose CPX test is limited by conditions other than pulmonary hypertension-associated dyspnea or fatigue.
  • Subjects who are known to be positive
  • Subjects with impairment of renal function (serum creatinine > 2.5x ) or hepatic function ( and/or AST > 3x ULN; and/or >= 2 mg/dL). Hematological abnormalities (e.g., severe anemia, \< 10 g/dL, leukopenia, WBC \< 2500/mL).
  • Subjects who previously received bosentan and whose liver function tests taken at screening are > 2x ULN.
  • Subjects with any medical condition which in the opinion of the investigator may interfere with treatment, evaluation of safety, and/or efficacy.
  • Change in class of medication for CHF or PAH within the 10 days prior to qualifying right heart catheterization.
  • Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in any form. Acute vasodilator testing with nitric oxide is permitted during hemodynamic evaluation; taking chronic arginine supplementation including Heart Bar; therapy involving parenteral inotropic medication or parenteral vasodilators within 3 months of screening; current therapy with alpha-blockers, potent cytochrome P450 3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole and protease inhibitors), Ritonavir or Nicorandil; chronic treatment with off-label sildenafil, an endothelin antagonist or prostacyclin/prostacyclin analogue within 30 days of randomization.
  • Pregnant or lactating female.
  • Any medical or psychological condition or social circumstances that would impair their ability to participate reliably in the study or who were not likely to complete the study for any reason; current or past illicit drug use or alcoholism excepting if abstinence can be documented for >= 1 year.
  • Participation in another clinical trial of an drug or device (including placebo) within 30 days of screening for entry into the present study.
  • Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    Sildenafil Low dose

    Drug: Sildenafil citrate

  • Experimental
    Sildenafil Medium dose

    Drug: Sildenafil citrate

  • Experimental
    Sildenafil High dose

    Drug: Sildenafil citrate

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population

    Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.

    Time frame: Baseline, Week 16

  2. Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population

    Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Change From Baseline to Week 16 in Mean Pulmonary Artery Pressure (mPAP)

    mPAP, a hemodynamic parameter, was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.

    Time frame: Baseline, Week 16

  2. Change From Baseline to Week 16 in Pulmonary Vascular Resistance Index (PVRI)

    PVRI equals Pulmonary Vascular Resistance (PVR) times Body Surface Area (BSA). Wood unit = 80dyn•s/cm5. Change is observed value at Week 16 minus Baseline value.

    Time frame: Baseline, Week 16

  3. Percent Change From Baseline to Week 16 in: Respiratory Exchange Ratio (RER)

    RER is the ratio of carbon dioxide produced to oxygen consumed \[VCO2/VO2\]). Percent change is \[(Week 16 value minus Baseline value)/Baseline value\] \* 100%

    Time frame: Baseline, Week 16

  4. Percent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2)

    Time to maximum VO2 was assessed on the subset of subjects who are developmentally able to perform the exercise test. Percent change is \[(value at Week 16 minus Baseline value)/Baseline value\] \* 100%

    Time frame: Baseline, Week 16

  5. Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)

    Change calculated as (mean PAP - PCWP)/COpulm in PVR is observed value at Week 16 minus Baseline value.

    Time frame: Baseline, Week 16

  6. Change From Baseline to Week 16 in Cardiac Index (CI)

    CI is observed value at Week 16 minus Baseline value. Calculated as cardiac output in systemic circulation (COsys) / body surface area (BSA).

    Time frame: Baseline, Week 16

  7. Change From Baseline to Week 16 in Right Atrial Pressure (RAP)

    RAP was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.

    Time frame: Baseline, Week 16

  8. Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Physical Scale

    CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.

    Time frame: Baseline, Week 16

  9. Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Psychosocial Scales

    CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.

    Time frame: Baseline, Week 16

  10. Change From Baseline to Week 16 in World Health Organization (WHO) Pulmonary Hypertension (PH) Functional Class

    WHO PH functional class definitions adapted from New York Heart Association Criteria for Functional Capacity and Therapeutic Class Definitions. Class I = PH without resulting limitation of physical activity, Class II = PH resulting in slight limitation of physical activity, Class III = PH resulting in marked limitation of physical activity, Class IV = PH with inability to carry out any physical activity without symptoms. Improved by 1 class = Class 4 to 3, Class 3 to 2, Class 2 to 1. Improved by 2 classes = Class 4 to 2, Class 3 to 1. Change is observed value at Week 16 minus Baseline value.

    Time frame: Baseline, Week 16

07

Results

Posted Jul 21, 2009

Participant flow

The study was conducted at 32 centers in North, Latin and South America, Europe and Asia.

Participant flow — Overall Study
MilestoneSildenafil Low DoseSildenafil Medium DoseSildenafil High DosePlacebo
Started42557760
Completed40557558
Not completed2022
Withdrew: Adverse event1010
Withdrew: Withdrawal by subject0001
Withdrew: Lost to follow-up0001
Withdrew: Protocol violation1010

Outcome measures

PrimaryPercent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population

Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population
percent changeSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population6.44 ± 20.1613.40 ± 19.5010.58 ± 15.5110.24 ± 18.390.53 ± 15.91
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.056 (No adjustments for multiple comparisons have been made.) · Mean difference (net): 7.71 · 95% CI -0.19 to 15.60Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates.
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (net): 3.81 · 95% CI -6.11 to 13.73Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates.
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (net): 11.33 · 95% CI 1.72 to 20.94Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates.
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (net): 7.98 · 95% CI -1.64 to 17.60Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates.
SecondaryChange From Baseline to Week 16 in Mean Pulmonary Artery Pressure (mPAP)

mPAP, a hemodynamic parameter, was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.

Time frame:
Baseline, Week 16
Reported as:
Mean · mm Hg
Change From Baseline to Week 16 in Mean Pulmonary Artery Pressure (mPAP)
mm HgSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Change From Baseline to Week 16 in Mean Pulmonary Artery Pressure (mPAP)0.9 ± 12.3-3.9 ± 12.0-7.4 ± 15.4-4.3 ± 13.9-0.4 ± 15.9
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.172 · Mean difference (final values): -3.1 · 95% CI -7.5 to 1.3Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met with main analysis: alternative=excluding outliers
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 1.6 · 95% CI -4.5 to 7.6Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met with main analysis: alternative=excluding outliers
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): -3.5 · 95% CI -8.9 to 1.9Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met with main analysis: alternative=excluding outliers
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): -7.3 · 95% CI -12.4 to -2.1Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met with main analysis: alternative=excluding outliers
SecondaryChange From Baseline to Week 16 in Pulmonary Vascular Resistance Index (PVRI)

PVRI equals Pulmonary Vascular Resistance (PVR) times Body Surface Area (BSA). Wood unit = 80dyn•s/cm5. Change is observed value at Week 16 minus Baseline value.

Time frame:
Baseline, Week 16
Reported as:
Mean · wood units. m2
Change From Baseline to Week 16 in Pulmonary Vascular Resistance Index (PVRI)
wood units. m2Sildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Change From Baseline to Week 16 in Pulmonary Vascular Resistance Index (PVRI)0.1 ± 10.9-2.9 ± 11.5-5.1 ± 14.7-3.2 ± 13.01.6 ± 9.2
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.041 · Mean difference (final values): -4.1 · 95% CI -8.0 to -0.2Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met w/ main analysis: alternative=natural log transformed
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): -0.6 · 95% CI -5.9 to 4.7Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met w/ main analysis: alternative=natural log transformed
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): -4.5 · 95% CI -9.3 to 0.3Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met w/ main analysis: alternative=natural log transformed
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): -7.2 · 95% CI -11.7 to -2.7Covariates:etiology, wt grp, capability performing exercise test. Normality assumptions not met w/ main analysis: alternative=natural log transformed
SecondaryPercent Change From Baseline to Week 16 in: Respiratory Exchange Ratio (RER)

RER is the ratio of carbon dioxide produced to oxygen consumed \[VCO2/VO2\]). Percent change is \[(Week 16 value minus Baseline value)/Baseline value\] \* 100%

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline to Week 16 in: Respiratory Exchange Ratio (RER)
percent changeSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Percent Change From Baseline to Week 16 in: Respiratory Exchange Ratio (RER)-0.00 ± 0.13-0.05 ± 0.12-0.02 ± 0.11-0.03 ± 0.12-0.03 ± 0.11
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.795 · Mean difference (final values): 0.61 · 95% CI -4.07 to 5.30The model included the covariates etiology and weight group
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 2.62 · 95% CI -3.31 to 8.54The model included the covariates etiology and weight group
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): -1.29 · 95% CI -7.09 to 4.50The model included the covariates etiology and weight group
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): 0.52 · 95% CI -5.24 to 6.28The model included the covariates etiology and weight group
SecondaryPercent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2)

Time to maximum VO2 was assessed on the subset of subjects who are developmentally able to perform the exercise test. Percent change is \[(value at Week 16 minus Baseline value)/Baseline value\] \* 100%

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2)
percent changeSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Percent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2)64.83 ± 103.6964.42 ± 102.7031.33 ± 107.0452.95 ± 104.408.84 ± 96.09
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.139 · Mean difference (final values): 9.24 · 95% CI -3.05 to 21.54The model included the covariates etiology and weight group
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 10.34 · 95% CI -5.21 to 25.90The model included the covariates etiology and weight group
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): 11.43 · 95% CI -3.78 to 26.64The model included the covariates etiology and weight group
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): 5.96 · 95% CI -9.16 to 21.08The model included the covariates etiology and weight group
SecondaryChange From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)

Change calculated as (mean PAP - PCWP)/COpulm in PVR is observed value at Week 16 minus Baseline value.

Time frame:
Baseline, Week 16
Reported as:
Mean · wood units
Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)
wood unitsSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)-0.1 ± 10.4-3.3 ± 10.5-5.2 ± 15.7-3.4 ± 13.10.1 ± 11.8
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.172 · Mean difference (final values): -2.9 · 95% CI -7.1 to 1.3The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 0.2 · 95% CI -5.5 to 5.9The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): -3.4 · 95% CI -8.5 to 1.7The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): -5.5 · 95% CI -10.3 to -0.7The model included the covariates etiology, weight group and capability of performing the exercise test
SecondaryChange From Baseline to Week 16 in Cardiac Index (CI)

CI is observed value at Week 16 minus Baseline value. Calculated as cardiac output in systemic circulation (COsys) / body surface area (BSA).

Time frame:
Baseline, Week 16
Reported as:
Mean · liters/minute/meters squared
Change From Baseline to Week 16 in Cardiac Index (CI)
liters/minute/meters squaredSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Change From Baseline to Week 16 in Cardiac Index (CI)0.20 ± 1.170.02 ± 1.440.24 ± 2.190.16 ± 1.76-0.60 ± 2.12
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.015 · Mean difference (final values): 0.74 · 95% CI 0.14 to 1.34The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 0.71 · 95% CI -0.10 to 1.52The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): 0.61 · 95% CI -0.12 to 1.35The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): 0.89 · 95% CI 0.21 to 1.58The model included the covariates etiology, weight group and capability of performing the exercise test
SecondaryChange From Baseline to Week 16 in Right Atrial Pressure (RAP)

RAP was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.

Time frame:
Baseline, Week 16
Reported as:
Mean · mm Hg
Change From Baseline to Week 16 in Right Atrial Pressure (RAP)
mm HgSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Change From Baseline to Week 16 in Right Atrial Pressure (RAP)7.92 ± 2.858.05 ± 4.427.75 ± 4.147.89 ± 3.958.11 ± 3.61
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.440 · Mean difference (final values): -0.50 · 95% CI -1.77 to 0.77The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): -0.17 · 95% CI -1.91 to 1.57The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): -0.19 · 95% CI -1.73 to 1.36The model included the covariates etiology, weight group and capability of performing the exercise test
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): -1.14 · 95% CI -2.61 to 0.33The model included the covariates etiology, weight group and capability of performing the exercise test
SecondaryChange From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Physical Scale

CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on scale
Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Physical Scale
score on scaleSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Physical Scale14.0 ± 13.19.8 ± 11.85.9 ± 10.59.4 ± 12.18.3 ± 12.0
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.750 · Mean difference (final values): -0.62 · 95% CI -4.45 to 3.21The covariates included in the model were baseline scale, etiology, weight and capability of performing the exercise test.
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 0.87 · 95% CI -4.21 to 5.95
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): 0.24 · 95% CI -4.68 to 5.15
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): -2.96 · 95% CI -7.37 to 1.45
SecondaryChange From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Psychosocial Scales

CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on scale
Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Psychosocial Scales
score on scaleSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Psychosocial Scales5.1 ± 6.94.1 ± 8.14.3 ± 10.04.5 ± 8.65.6 ± 10.3
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.784 · Mean difference (final values): -0.42 · 95% CI -3.41 to 2.58The covariates included in the model were baseline scale, etiology, weight and capability of performing the exercise test.
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 0.41 · 95% CI -3.49 to 4.30
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): -2.11 · 95% CI -5.99 to 1.77
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): 0.46 · 95% CI -3.06 to 3.97
SecondaryChange From Baseline to Week 16 in World Health Organization (WHO) Pulmonary Hypertension (PH) Functional Class

WHO PH functional class definitions adapted from New York Heart Association Criteria for Functional Capacity and Therapeutic Class Definitions. Class I = PH without resulting limitation of physical activity, Class II = PH resulting in slight limitation of physical activity, Class III = PH resulting in marked limitation of physical activity, Class IV = PH with inability to carry out any physical activity without symptoms. Improved by 1 class = Class 4 to 3, Class 3 to 2, Class 2 to 1. Improved by 2 classes = Class 4 to 2, Class 3 to 1. Change is observed value at Week 16 minus Baseline value.

Time frame:
Baseline, Week 16
Reported as:
Number · units
Change From Baseline to Week 16 in World Health Organization (WHO) Pulmonary Hypertension (PH) Functional Class
unitsSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
No change2524388431
Improved by 1 class61016324
Improved by 2 classes00110
Statistical analysis
  • Combined Sildenafil vs Placebo · Regression, Logistic · p = 0.184 · Odds ratio (or): 1.83 · 95% CI 0.75 to 4.45Proportional odds method. Model covariates were baseline WHO functional class, etiology, weight group and capability of performing the exercise test.
  • Sildenafil Low Dose vs Placebo · Regression, Logistic · p = 0.409 · Odds ratio (or): 0.60 · 95% CI 0.18 to 2.01Proportional odds method. Model covariates were baseline WHO functional class, etiology, weight group and capability of performing the exercise test.
  • Sildenafil Medium Dose vs Placebo · Regression, Logistic · p = 0.146 · Odds ratio (or): 2.25 · 95% CI 0.75 to 6.69Proportional odds method. Model covariates were baseline WHO functional class, etiology, weight group and capability of performing the exercise test.
  • Sildenafil High Dose vs Placebo · Regression, Logistic · p = 0.006 · Odds ratio (or): 4.52 · 95% CI 1.56 to 13.10Proportional odds method. Model covariates were baseline WHO functional class, etiology, weight group and capability of performing the exercise test.
PrimaryPercent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population

Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population
percent changeSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population5.43 ± 20.6915.66 ± 21.489.34 ± 17.1310.10 ± 19.872.81 ± 13.17
Statistical analysis
  • Combined Sildenafil vs Placebo · ANCOVA · p = 0.179 · Mean difference (final values): 5.89 · 95% CI -2.74 to 14.53Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates
  • Sildenafil Low Dose vs Placebo · ANCOVA · Mean difference (final values): 1.14 · 95% CI -9.49 to 11.77Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates
  • Sildenafil Medium Dose vs Placebo · ANCOVA · Mean difference (final values): 11.30 · 95% CI 0.66 to 21.96Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates
  • Sildenafil High Dose vs Placebo · ANCOVA · Mean difference (final values): 5.24 · 95% CI -5.02 to 15.50Analyses performed using analysis of covariance with etiology, weight and baseline peak VO2 as the covariates

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sildenafil Low Dose———
Sildenafil Medium Dose———
Sildenafil High Dose———
Combined Sildenafil———
Placebo———
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
PneumoniaInfections and infestations0/421/552/773/1740/60
CyanosisCardiac disorders1/420/550/771/1740/60
HaematocheziaGastrointestinal disorders1/420/550/771/1740/60
SyncopeNervous system disorders1/420/550/771/1740/60
DyspnoeaRespiratory, thoracic and mediastinal disorders1/420/550/771/1740/60
Upper respiratory tract infectionInfections and infestations0/421/551/772/1740/60
DiarrhoeaGastrointestinal disorders0/420/550/770/1741/60
Pneumonia bacterialInfections and infestations0/420/550/770/1741/60
BradycardiaCardiac disorders0/420/551/771/1740/60
Cardiac failure congestiveCardiac disorders0/420/551/771/1740/60
Most frequent other events
Showing 10 of 33
Most frequent other events
EventSildenafil Low DoseSildenafil Medium DoseSildenafil High DoseCombined SildenafilPlacebo
HeadacheNervous system disorders5/426/5512/7723/1748/60
Upper respiratory tract infectionInfections and infestations4/428/556/7718/1744/60
PyrexiaGeneral disorders3/428/558/7719/1741/60
VomitingGastrointestinal disorders3/425/5511/7719/1744/60
DiarrhoeaGastrointestinal disorders2/423/557/7712/1744/60
BronchitisInfections and infestations2/425/553/778/1741/60
NauseaGastrointestinal disorders0/424/554/778/1740/60
CoughRespiratory, thoracic and mediastinal disorders2/424/552/778/1743/60
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/424/552/776/1740/60
NasopharyngitisInfections and infestations3/423/552/778/1744/60

Baseline characteristics

Age, Customized
Age, Customized(participants)Sildenafil Low DoseSildenafil Medium DoseSildenafil High DosePlaceboTotal
1-4 Years0919735
5-12 Years25283637126
13-17 Years1718221673
>= 18 Years00000
Sex: Female, Male
Sex: Female, Male(Participants)Sildenafil Low DoseSildenafil Medium DoseSildenafil High DosePlaceboTotal
Female25315138145
Male1724262289
08

Study locations

41 sites
  • Pfizer Investigational Site
    Palo Alto, California 94304, United States
  • Pfizer Investigational Site
    Stanford, California 94305, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80045, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02115, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63110, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43205, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29425, United States
  • Pfizer Investigational Site
    Seattle, Washington 98105, United States
  • Pfizer Investigational Site
    São Paulo, SP 04012-909, Brazil
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • Pfizer Investigational Site
    Santiago, RM, Chile
  • Pfizer Investigational Site
    Medellin, Antioquia 0, Colombia
  • Pfizer Investigational Site
    Bogota, Cundinamarca 0, Colombia
  • Pfizer Investigational Site
    Guatemala, Guatemala
  • Pfizer Investigational Site
    Budapest, 1083, Hungary
  • Pfizer Investigational Site
    Budapest, 1096, Hungary
  • Pfizer Investigational Site
    Deszk, 6722, Hungary
  • Pfizer Investigational Site
    Szeged, 6720, Hungary
  • Pfizer Investigational Site
    Szeged, 6726, Hungary
  • Pfizer Investigational Site
    Hyderabad, Andra Pradesh 500 001, India
  • Pfizer Investigational Site
    Kerala, Kochi, 682 026, India
  • Pfizer Investigational Site
    Bologna, 40138, Italy
  • Pfizer Investigational Site
    Tokyo, Japan
  • Pfizer Investigational Site
    Penang, 10050, Malaysia
  • Pfizer Investigational Site
    Penang, 10900, Malaysia
  • Pfizer Investigational Site
    Del. Tlalpan, Mexico D.F. 14080, Mexico
  • Pfizer Investigational Site
    Tlalpan, Mexico DF 14080, Mexico
  • Pfizer Investigational Site
    Lima, L13, Peru
  • Pfizer Investigational Site
    Krakow, 30-663, Poland
  • Pfizer Investigational Site
    Krakow, 31-202, Poland
  • Pfizer Investigational Site
    Warszawa, 04-628, Poland
  • Pfizer Investigational Site
    Warszawa, 04-730, Poland
  • Pfizer Investigational Site
    Zabrze, 41-800, Poland
  • Pfizer Investigational Site
    Moscow, 121552, Russian Federation
  • Pfizer Investigational Site
    Moscow, 127412, Russian Federation
  • Pfizer Investigational Site
    Lund, 221 85, Sweden
  • Pfizer Investigational Site
    Kaohsiung, 81346, Taiwan
  • Pfizer Investigational Site
    Taipei, 100, Taiwan
  • Pfizer Investigational Site
    Taipei, 11217, Taiwan
09

References and documents

Publications

  • Russell S, Beghetti M, Oudiz R, Balagtas C, Zhang M, Ivy D. Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial. Open Heart. 2019 Dec 3;6(2):e001149. doi: 10.1136/openhrt-2019-001149. eCollection 2019. PubMed 31908813 ↗
  • Chanu P, Gao X, Bruno R, Claret L, Harnisch L. A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):499-509. doi: 10.1007/s10928-019-09654-3. Epub 2019 Sep 20. PubMed 31538282 ↗
  • Beghetti M, Rudzinski A, Zhang M. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension. BMC Cardiovasc Disord. 2017 Jul 4;17(1):177. doi: 10.1186/s12872-017-0569-3. PubMed 28676038 ↗
  • Cappelleri JC, Hwang LJ, Mardekian J, Mychaskiw MA. Assessment of measurement properties of peak VO(2) in children with pulmonary arterial hypertension. BMC Pulm Med. 2012 Sep 10;12:54. doi: 10.1186/1471-2466-12-54. PubMed 22963001 ↗
  • Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012 Jan 17;125(2):324-34. doi: 10.1161/CIRCULATIONAHA.110.016667. Epub 2011 Nov 29. PubMed 22128226 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Aug 2003
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jul 21, 2009
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00159913
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Aug 2003
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jul 21, 2009
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion